Karen D. Neuendorff

Brii Biosciences Ltd. is a biotechnology company, which engages in the provision of healthcare solutions. It focuses on the development of therapies for infectious diseases such as hepatitis B, COVID-19, human immunodeficiency virus (HIV) infection, multi-drug resistant (MDR) or extensive drug resistant (XDR) gram-negative infections, and other illnesses, such as the central nervous system (CNS) diseases. The company was founded by Zhi Hong in 2018 and is headquartered in Durham, NC.

Brii Biosciences Ltd. is a biotechnology company, which engages in the provision of healthcare solutions. It focuses on the development of therapies for infectious diseases such as hepatitis B, COVID-19, human immunodeficiency virus (HIV) infection, multi-drug resistant (MDR) or extensive drug resistant (XDR) gram-negative infections, and other illnesses, such as the central nervous system (CNS) diseases. The company was founded by Zhi Hong in 2018 and is headquartered in Durham, NC.

Brii Biosciences Ltd. is a biotechnology company, which engages in the provision of healthcare solutions. It focuses on the development of therapies for infectious diseases such as hepatitis B, COVID-19, human immunodeficiency virus (HIV) infection, multi-drug resistant (MDR) or extensive drug resistant (XDR) gram-negative infections, and other illnesses, such as the central nervous system (CNS) diseases. The company was founded by Zhi Hong in 2018 and is headquartered in Durham, NC.

Brii Biosciences Ltd. is a biotechnology company, which engages in the provision of healthcare solutions. It focuses on the development of therapies for infectious diseases such as hepatitis B, COVID-19, human immunodeficiency virus (HIV) infection, multi-drug resistant (MDR) or extensive drug resistant (XDR) gram-negative infections, and other illnesses, such as the central nervous system (CNS) diseases. The company was founded by Zhi Hong in 2018 and is headquartered in Durham, NC.

Brii Biosciences Ltd. is a biotechnology company, which engages in the provision of healthcare solutions. It focuses on the development of therapies for infectious diseases such as hepatitis B, COVID-19, human immunodeficiency virus (HIV) infection, multi-drug resistant (MDR) or extensive drug resistant (XDR) gram-negative infections, and other illnesses, such as the central nervous system (CNS) diseases. The company was founded by Zhi Hong in 2018 and is headquartered in Durham, NC.